Gecacitinib-Corticosteroid
Phase 2Small molecule
Gecacitinib-Corticosteroid is one of 9 small molecule programs targeting Acute Graft Versus Host Disease. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
11 competitors in Acute Graft Versus Host Disease
#DrugCompanyPhaseTrials
1Jakafi
IncyteApproved
Stelara
Johnson & JohnsonPhase 2
Solu-Medrol
MMassachusetts Eye and Ear Infirmary
Phase 2
Arava
SanofiPhase 1
Gecacitinib
SSuzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 2
Questran
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 1
MC0518
Mmedac GmbH
Phase 2
Gecacitinib-Corticosteroid
BBin Gu
Phase 2
Inolimomab
EElsaLys Biotech
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Gecacitinib-Corticosteroid. EMBL-EBI & Wellcome Sanger Institute.
- [4]